Yes, stem cell therapy can cause side effects. The risks depend on the cell type, how the cells are collected and prepared, how they are delivered and how well the clinic manages its process. The US Food and Drug Administration (FDA) has received reports of blindness, tumor formation and serious infections linked to unapproved stem cell products. Japan requires clinics to report serious suspected treatment-related events within fixed deadlines, but a reporting rule does not make a treatment safe.

Where the risks come from

The risks follow the treatment path, so it helps to split them by stage.

Collection. If the cells come from the patient, the first step is collecting tissue, such as fat through a small procedure or bone marrow through a needle. Collection carries the ordinary risks of a minor procedure, including pain, bleeding, bruising and local infection.

Preparation. Cultured cells are grown in a facility, and contamination or a shift in cell characteristics during culture can cause problems. The FDA's warning on unapproved products lists bacterial infections, including life-threatening blood infections.

Infusion or injection. Delivery methods vary, and each has its own profile. Possible reactions include local pain or swelling, fever and allergic responses. The treating team should describe the specific delivery method and its known reactions.

The cells themselves. Donor cells can trigger an immune response, because the recipient's immune system may recognize them as foreign. Japan places donor-derived cell therapy in Class I, the highest risk class. Pluripotent cells, such as those derived from iPS or embryonic stem cells, raise a separate concern about tumor formation. The FDA's warning includes reports of tumor formation linked to unapproved products.

What the FDA says about unapproved products

The FDA's consumer page on regenerative medicine therapies makes several points that matter for readers considering a clinic offering:

A woman and a young boy sit across a desk from a doctor in a white coat, with pill bottles and a clipboard on the desk.

  • Products of this kind require FDA licensure or approval to be marketed to consumers.
  • Patients who are charged for these products, or offered them outside a clinical trial, are described as likely being deceived and offered an illegal product.
  • The products have not been adequately studied under an investigational new drug (IND) application to demonstrate safety and effectiveness.
  • The FDA reports receiving reports of blindness, tumor formation, infections and other harms.

The FDA's list of licensed cellular and gene therapy products, updated 30 October 2026, includes HPC cord blood products and RYONCIL, a mesenchymal stromal cell product. Our FDA-approved stem cell treatments article covers the wider list.

Risks that are not medical side effects

Uncertain benefit. For most stem cell uses, a benefit has not been shown in controlled trials. A treatment that causes no harm may still not help. The risk is that a patient pays, travels and waits for a benefit the evidence does not support.

Cost. Most regenerative treatment in Japan is self-pay free treatment, and the clinic sets the price. Travel, lodging, interpretation and multiple visits add to the total. Plan for those costs before deciding.

Missed alternatives. A stem cell offering may delay a proven treatment or make it harder to join a legitimate clinical trial later. Discuss the alternatives with your current doctor before committing.

What Japan requires clinics to report

Under the Safety Act, a clinic that learns of a suspected illness, disability, death or infection caused by a regenerative treatment must report it within fixed deadlines. The Enforcement Regulations set the following for the most serious categories:

An older man in a checkered shirt and a woman in a white lab coat with a stethoscope sit across a desk from each other, with a document, pill bottles, and a laptop between them in an office with shelves and a poster.

  • Death, or a case that could lead to death: report within 7 days of learning of it, to the review committee and the Minister of Health, Labour and Welfare.
  • Hospitalization or a longer hospital stay, disability or a case that could lead to disability, and other serious cases: report within 15 days.

For Class II and Class III treatments, the regional health and welfare bureau receives the reports addressed to the Minister. MHLW also opened a regenerative medicine information and reporting window on 2 September 2026, which accepts reports of suspected violations and safety concerns.

These rules matter because a compliant clinic has a defined path for handling a reaction. A clinic that has not filed a plan has no such process to rely on. Reporting rules describe what must happen after a serious event. They do not show how often events happen, and they do not show that a treatment is free of risk.

What to ask before treatment

  1. Which class is this treatment under the Safety Act, and which committee reviewed the plan?
  2. Are the cells from my body or from a donor? How were they collected, cultured and tested?
  3. What delivery method is used, and what reactions are most common with it?
  4. What happens if I develop a fever, infection or other symptom while in Japan and after I return home? Who do I call, and how fast will they respond?
  5. What human evidence exists for my specific condition, and what outcome was measured?
  6. What does the total cost include, and what happens to the plan if I need to stop midway?

A person in a hospital gown seated in a wheelchair being pushed by a staff member in blue scrubs down a clinical hallway past an empty stretcher and a wall-mounted telephone.

If the answers are vague, or the clinic says the treatment has no side effects, treat that as a warning sign. You can send the clinic's name and the treatment description to our advisors, and we will check whether the clinic has filed a provision plan for that treatment. For the regulatory background, see our how Japan regulates regenerative medicine page. For the wider process, see medical tourism in Japan.

Frequently asked questions

Can stem cell therapy cause harm?

Yes. Stem cell therapy can cause reactions at the collection, preparation and delivery stages, and it can cause immune reactions with donor cells. The FDA has received reports of blindness, tumor formation and infections linked to unapproved stem cell products.

Is stem cell therapy safe if the cells come from my own body?

Own-cell therapy avoids the immune mismatch that comes with donor cells, but it still carries the risks of collection, culture contamination and delivery. A patient's own cells do not remove those risks.

What must a Japanese clinic do if a patient has a serious reaction?

Under the Safety Act, the clinic must report a death or a possible death within 7 days, and a hospitalization, disability or other serious case within 15 days, to the review committee and the Ministry. The clinic should also discuss how to handle the event with you before treatment begins.

Does reporting make a treatment safe?

No. Reporting rules show what must be done after a serious event. They do not measure how often events occur or show that the treatment is free of risk.

Who should I talk to about side effects before I travel?

Talk to your current doctor about the treatment and its alternatives, and get a written plan from the clinic for managing reactions in Japan and after you return home.

Sources: FDA, "Important Patient and Consumer Information About Regenerative Medicine Therapies"; FDA, "Approved Cellular and Gene Therapy Products"; FDA, "HPC, Cord Blood"; Japan Act on the Safety of Regenerative Medicine (Act No. 85 of 2013) and Enforcement Regulations, Arts. 2–3 and 35–36 (e-Gov text); MHLW, "Regenerative Medicine, Cell Therapy and Gene Therapy" page, including the 2 September 2026 reporting window notice. Checked November 2026; MHLW (or the relevant body) publications prevail.

Medical disclaimer: This site provides general information only and does not constitute medical advice; whether any treatment is suitable for you must be decided by a doctor after an in-person consultation.